Higher Dose Imatinib for Children With De Novo Chronic Phase Chronic Myelogenous Leukemia: A Report From the Children’s Oncology Group

PURPOSE: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). METHODS: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Champagne, Martin A., Fu, Cecilia H., Chang, Myron, Chen, Helen, Gerbing, Robert B., Alonzo, Todd A., Cooley, Linda D., Heerema, Nyla A., Oehler, Vivian, Wood, Charlotte, French, Mary Ellen, Arceci, Robert J., Smith, Franklin O., Bernstein, Mark L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5157124/
https://ncbi.nlm.nih.gov/pubmed/21465636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23031
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky